LAVAL, Quebec, June 18, 2018 /PRNewswire/ — Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX), today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug…Original Article
FDA Issues Complete Response Letter for Duobrii (halobetasol propionate and tazarotene) Lotion
